Compare LGVN & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LGVN | MDCX |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | United States | United States |
| Employees | N/A | 12 |
| Industry | Medicinal Chemicals and Botanical Products | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.9M | 13.9M |
| IPO Year | 2021 | N/A |
| Metric | LGVN | MDCX |
|---|---|---|
| Price | $0.94 | $0.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $3.00 | ★ $23.50 |
| AVG Volume (30 Days) | ★ 8.9M | 8.8M |
| Earning Date | 03-17-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.76 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $709,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,183.95 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.48 | $0.37 |
| 52 Week High | $1.83 | $8.90 |
| Indicator | LGVN | MDCX |
|---|---|---|
| Relative Strength Index (RSI) | 58.29 | 28.10 |
| Support Level | $0.55 | $0.37 |
| Resistance Level | $1.44 | $1.70 |
| Average True Range (ATR) | 0.14 | 0.05 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 44.55 | 3.25 |
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.